Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Induction of apoptosis by reactivation of p53 in cancer cells is an emerging therapeutic concept for the treatment of cancer. The discovery and design of novel small molecules that block the p53-Mdm2 protein interaction, thereby activating p53, has provided interesting drug candidates that have currently entered clinical trials or are at the preclinical development stage. AREAS COVERED IN THIS REVIEW: A selection of the interesting patents focusing on small molecule inhibitors of the p53-Mdm2 interaction, recorded from 2006 until 2009, is presented together with a review of the related structural chemistry space. WHAT THE READER WILL GAIN: Readers will rapidly gain an overview of the majority of patented scaffolds of small molecule inhibitors of the p53-Mdm2 protein-protein interaction and learn about current limitations and properties of these compounds. TAKE HOME MESSAGE: The discovery p53-Mdm2 protein-protein interaction inhibitors have delivered new potential options for a targeted cancer therapy with drug-like, non-toxic small molecules. If successful, this approach could gain considerably more attention in the pharmaceutical industry by targeting a variety of validated intracellular protein-protein interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · cited 3×
“Spiroindolinones The idea of oxindoles and the need for U-shaped structures led to the design of spiro compounds with an indolinone as the major binding motif, as exemplified by scientists at the University of Michigan in the group of Shaomeng Wang with compounds (16, MI-43), (17, MI-63) and (18, MI-219) [24,25].”
BackgroundInactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · cited 1×
“The Mdm2 NH2 terminus and central domain are the contact sites for p53, while the RING domain of Mdm2 is the primary binding site for E2 ligases [4].”
Background
Cited by
miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress
Xiao, J., Lin, H., Luo, X., Luo, X., & Wang, Z. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.347 · Cited by 189
Resistance acquisition to MDM2 inhibitors
Cinatl, J., Speidel, D., Hardcastle, I., & Michaelis, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140035 · Cited by 30
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- Weber, L.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa Healthcare
- Published
- 2010-01-25
- Volume
- 20
- Issue
- 2
- Pages
- 179-191
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2113146796
- Cited by
- 44
- References
- 3
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patented inhibitors of p53–Mdm2 interaction (2006 – 2008). https://app.cochat.ai/papers/10.1517/13543770903514129
- The paper
- Weber, L. (2010). Patented inhibitors of p53–Mdm2 interaction (2006 – 2008). Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543770903514129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.